Decrease of muscle weakness and degeneration with mutants of UPS components. by Cécile Ribot (11944875)

Decreased deaminase activity in A12-infected cells despite a high level of A3B protein. by Noémie Lejeune (9243785)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

“…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". The following acronyms included in the CSV file are defined as follows: Hbt is total hemoglobin, Art is artery region, DV is draining vein region, WV is whisker vein region, SEM is standard error mean, TS is time series, max peak is maximum peak, min peak is minima, AUC is area under the curve, WT is wild-type, AD is Alzheimer's disease, ATH is atherosclerosis and MIX is mixed AD/atherosclerosis. …”

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

<i>T</i>. <i>spiralis</i> Infection Enhanced Residential Tregs in Lamina Propria of the Large Intestine. by Xi-Meng Sun (17721428)

Triple B←N Lewis Pair-Functionalized Triazatruxenes with Large Stokes Shifts by Yufeng Zhang (195768)

Subjects:

Large prairie patches. by Megan P. Vhay (18707751)

Large-scale filtration system data. by Haedi E. DeAngelis (10652168)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Decreased MBP levels in the brain in <i>Large</i>^{<i>myd/myd</i>} mice. by Shigefumi Morioka (8893511)

“…<p><b>A,</b> Brain sections of eight-week-old control and <i>Large</i>^{<i>myd/myd</i>} mice at the level of the corpus callosum were obtained for immunostaining for MBP (Scale bars: 200 μm). …”

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Schematic of Large-Scale Filtration System (LSFS). by Haedi E. DeAngelis (10652168)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Cyclooxygenase inhibition decreases immune control of fungal germination and invasive hyphal growth. by Savini Thrikawala (5690510)

The decrease in embryonic survival after stress coincides with a decrease in oocyte and embryo size. by Sarah Fausett (11812818)